DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer
Authors:
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 501, 224-233
Abstract
No abstract availableKeywords
Funding Information
- Faculty of Medicine
- Tel Aviv University
This publication has 45 references indexed in Scilit:
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not AnticipateCancer Cell, 2012
- Diagnosis of Serous Tubal Intraepithelial Carcinoma Based on Morphologic and Immunohistochemical FeaturesAmerican Journal of Surgical Pathology, 2011
- Mitochondrial ATP synthase: architecture, function and pathologyJournal of Inherited Metabolic Disease, 2011
- 3, 3′5 Triiodo L Thyronine Induces Apoptosis in Human Breast Cancer MCF-7cells, Repressing SMP30 Expression through Negative Thyroid Response ElementsPLOS ONE, 2011
- Mammalian forebrain ketimine reductase identified as μ‐crystallin; potential regulation by thyroid hormonesJournal of Neurochemistry, 2011
- Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNaseProceedings of the National Academy of Sciences, 2010
- Molecular Aspects of Thyroid Hormone ActionsEndocrine Reviews, 2010
- Understanding the Warburg Effect: The Metabolic Requirements of Cell ProliferationScience, 2009
- The Thyroid Hormone-Inactivating Deiodinase Functions as a HomodimerMolecular Endocrinology, 2008
- Sonic hedgehog-induced type 3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytesProceedings of the National Academy of Sciences, 2007